Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/192290
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVázquez Sánchez, Daniel Antonio-
dc.contributor.authorGrillo, Sara-
dc.contributor.authorCarrera Salinas, Anna-
dc.contributor.authorGonzález Díaz, Aida-
dc.contributor.authorCuervo Requena, Guillermo-
dc.contributor.authorGrau, Inmaculada-
dc.contributor.authorCamoez, Mariana-
dc.contributor.authorMartí, Sara-
dc.contributor.authorBerbel, Dàmaris-
dc.contributor.authorTubau, Fe-
dc.contributor.authorArdanuy Tisaire, María Carmen-
dc.contributor.authorPujol, Miquel-
dc.contributor.authorCàmara, Jordi-
dc.contributor.authorDomínguez Luzón, Ma. Ángeles (María Ángeles)-
dc.date.accessioned2023-01-18T17:46:41Z-
dc.date.available2023-01-18T17:46:41Z-
dc.date.issued2022-12-03-
dc.identifier.issn2076-2607-
dc.identifier.urihttp://hdl.handle.net/2445/192290-
dc.description.abstractMethicillin-resistant Staphylococcus aureus bloodstream infections (MRSA-BSI) are a significant cause of mortality. We analysed the evolution of the molecular and clinical epidemiology of MRSA-BSI (n = 784) in adult patients (Barcelona, 1990-2019). Isolates were tested for antimicrobial susceptibility and genotyped (PFGE), and a selection was sequenced (WGS) to characterise the pangenome and mechanisms underlying antimicrobial resistance. Increases in patient age (60 to 71 years), comorbidities (Charlson's index > 2, 10% to 94%), community-onset healthcare-associated acquisition (9% to 60%), and 30-day mortality (28% to 36%) were observed during the 1990-1995 and 2014-2019 periods. The proportion of catheter-related BSIs fell from 57% to 20%. Current MRSA-BSIs are caused by CC5-IV and an upward trend of CC8-IV and CC22-IV clones. CC5 and CC8 had the lowest core genome proportions. Antimicrobial resistance rates fell, and only ciprofloxacin, tobramycin, and erythromycin remained high (>50%) due to GyrA/GrlA changes, the presence of aminoglycoside-modifying enzymes (AAC(6 ')-Ie-APH(2 '')-Ia and ANT(4 ')-Ia), and mph(C)/msr(A) or erm (C) genes. Two CC22-IV strains showed daptomycin resistance (MprF substitutions). MRSA-BSI has become healthcare-associated, affecting elderly patients with comorbidities and causing high mortality rates. Clonal replacement with CC5-IV and CC8-IV clones resulted in lower antimicrobial resistance rates. The increased frequency of the successful CC22-IV, associated with daptomycin resistance, should be monitored.-
dc.format.extent14 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherMDPI AG-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/microorganisms10122401-
dc.relation.ispartofMicroorganisms, 2022, vol. 10, num. 12, p. 2401-
dc.relation.urihttps://doi.org/10.3390/microorganisms10122401-
dc.rightscc by (c) Vázquez Sánchez, Daniel Antonio et al., 2022-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Medicina)-
dc.subject.classificationStaphylococcus aureus-
dc.subject.classificationEpidemiologia molecular-
dc.subject.classificationAgents antiinfecciosos-
dc.subject.classificationResistència als medicaments-
dc.subject.otherStaphylococcus aureus-
dc.subject.otherMolecular epidemiology-
dc.subject.otherAnti-infective agents-
dc.subject.otherDrug resistance-
dc.titleMolecular Epidemiology, Antimicrobial Susceptibility, and Clinical Features of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections over 30 Years in Barcelona, Spain (1990–2019)-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2023-01-16T11:39:41Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid36557654-
Appears in Collections:Articles publicats en revistes (Medicina)
Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
microorganisms-10-02401.pdf2.52 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons